China Hosts Five Clinical Trials for COVID-19 Vaccines
Researched by Industrial Info Resources (Sugar Land, Texas)--Chinese pharmaceutical company Walvax Biotechnology Company Limited recently was approved to perform clinical trials for its recombinant coronavirus vaccine, according to Chinese National Medical Products Administration. To date, 640 million Chinese citizens have received a vaccine for COVID-19.
Chinese authorities also pointed to clinical trials from Anhui Zhifei Longcom, Cansino Biologics Incorporated and the Institute of Bioengineering (Academy of Military Medical Sciences).
Industrial Info is tracking a pair of COVID-19 vaccine-production projects, worth $157 million, which could add 1.62 billion doses per year. Subscribers to Industrial Info's Global Market Intelligence (GMI) Pharmaceutical & Biotech Project Database can click here for a list.
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, six offices in North America and 12 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. Follow IIR on: Facebook - Twitter - LinkedIn.